Janssen Biotech, Inc.

Andressa Smith

Michael Quigley

Alexey Teplyakov

Johan Fransson

Hong Mimi Zhou

Paul H Kim

Paul Kim

Hong Zhou

The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.

Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer

The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.

Agonistic antibodies specifically binding CD40 and methods of use

Growing community of inventors

Lansdale, PA, United States of America

Andressa Smith